Rituximab in the Treatment of Patients With Bullous Pemphigoid

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Duke University
Study ID
NCT00286325
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Bullous Pemphigoid

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    Infusion of 1000 mg of rituximab on day 0 and day 14

Study Details

This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.

Key Dates

Start date
Mar 31, 2005
Status verified
Sep 2012
Primary completion
Mar 31, 2010
Completion
Mar 31, 2010

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Rituximab
    Open label study all subjects treated with rituximab

Primary Outcome Measure

Primary Safety Endpoint [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
Duke University Medical CenterDurhamNorth Carolina27710-

Find similar trials in Durham, NC

By research site
Duke University Medical Center· Durham, NC

Related Studies